Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
FEBS Lett. Author manuscript; available in PMC 2014 May 21.
Published in final edited form as:
PMCID: PMC4029356

Attenuation of fibroblast growth factor signaling by poly-N-acatyllactosamine type glycans


Fibroblast growth factors (FGFs) and their receptors are expressed in a variety of mammalian tissues, playing a role in development and cell proliferation. While analyzing human sperm motility, we found that sperm treated with endo-β-galactosidase (EBG), which specifically hydrolyzes poly-N-acetyllactosamine type glycans (polyLacs), enhanced motility. Mass spectrometry analysis revealed that sperm-associated polyLacs are heavily fucosylated, consistent with Lewis Y antigen. Immunohistochemistry of epididymis using an anti-Lewis Y antibody before and after EBG treatment suggested that polyLacs carrying the Lewis Y epitope are synthesized in epididymal epithelia and secreted to seminal fluid. EBG-treated sperm elevated cAMP levels and calcium influx, indicating activation of fibroblast growth factor signaling. Seminal fluid polyLacs bound to FGFs in vitro, and impaired FGF-mediated signaling in HEK293T cells.

1. Introduction

Poly-N-acetyllactosamine type glycans (polyLacs) are large carbohydrates composed of galactose and N-acetylglucosamine repeats. PolyLacs were specifically detected due to their susceptibility to endo-β-galactosidase (EBG) [16]. They often carry blood group or onco-developmental antigens [3,79], which are detected by specific monoclonal antibodies directed to these carbohydrate antigens. PolyLacs and their modified forms are recognized as antigens, i. e., sialyl Lewis X and Lewis Y. These antigenic glycans reportedly function in cell-cell interaction during embryogenesis, tumorigenesis and cancer metastasis [1012].

Because of their large size, polyLacs protect core glycoproteins from proteolysis [13]. Two lysosomal membrane proteins, LAMP1 and LAMP2, are heavily glycosylated with polyLacs [14]. Mice deficient in Lamp2 accumulate autophagic vacuoles in many tissues and die prematurely of cardiomyopathy [15]. PolyLacs are likely essential for survival of mammalian cells in vitro, since no polyLac-deficient cell line has been generated. Polylacs are synthesized by sequential activity of B4GALT1 plus either B3GNT2 [1619], B3GNT4 [18], B3GNT7 [20,21], and B3GNT8 [16]. B3gnt2 knockout mice exhibit shorter polylac chains than do wild-type mice, and their T-lymphocytes exhibit increased calcium flux and cell proliferation, suggestive of hyperactivation [16]. There are as yet no reports of mutant mice completely lacking polyLacs.

Previous studies, including our own, suggested that mature human sperm cells are densely covered by carbohydrates [22,23]. While we attempted to remove glycans from living human spermatozoa using glycosidases, we found human sperm cells treated with endo-β-galactosidase (EBG) moved more rapidly than untreated sperm. We investigated the mechanism underlying EBG-triggered sperm motility and found that seminal fluid polyLacs down regulate sperm motility by impairing fibroblast growth factor-dependent signaling.

2. Materials and Methods

2.1. Reagents

EBG from Escherichia freundii was obtained from Seikagaku Co.Ltd (Tokyo Japan) and also purified from culture medium of E. freundii, as described [24]. Bovine corneal keratan sulfate was prepared as described previously [4,25]. Monoclonal anti-Lewis Y antibody (clone AH6, mouse IgM) [26] was provided by Dr. S. Hakomori, University of Washington, Seattle, WA. Recombinant human FGF1 (acidic-FGF) and FGF2 (basic-FGF) were obtained from Invitrogen/Life Technologies.

2.2. Human sperm and seminal fluid samples

Sperm and seminal fluid samples were obtained for future research use from 20 study volunteers, who provided verbal informed consent to participate in this study. Written consent was not obtained, as semen sample collection involves minimum health risk to human subject. Samples were given number codes to protect donor identity, and records were kept in a secure computer not accessible under any condition including by the internet. The ethics committee of the Hamamatsu Red Cross Hospital and that of Hamamatsu University School of Medicine approved the consent procedure. Donor fertility was not tested, nor did we undertake normal semen analysis. Sperm was mixed with sperm freezing solution from Irvine Scientific (Santa Ana, CA) and frozen until analyzed.

2.3. Sperm motility analysis

Sperm motility was analyzed using a SQA-V, sperm quality analyzer-v [27] (Medical Electronic Systems). Cryopreserved human sperm from healthy volunteers were washed with sperm washing medium (Irvine Biologicals) and suspended in the same solution. EBG was dissolved in water at 1 mUnit/ml. To 100 µl of human sperm solution (2×10^6 cells), 5 µl EBG was added at final concentration 50 µUnits/ml, and incubated at room temperature for 15 min. A sperm aliquot was placed in a 500 µl SQA-V Measurement Capillary. Statistical analysis was performed using a paired two-tailed Student’s t-test using the Prism program (GraphPad Software).

2.4. Measurement of calcium influx and cAMP

Calcium influx into sperm cells was measured using a Fluo-4 NW calcium assay kit (Molecular Probes). Sperm cells treated or untreated with EBG were assayed in triplicate in 96-well plates. Fluorescence was measured using a Beckman DTX810 plate reader, using excitation and emission wavelengths of 495nm and 519 nm, respectively. Cyclic AMP was measured using a competition-based immunoassay kit for cyclic AMP and GMP XP (Cell Signaling).

2.5. Preparation of sperm-associated glycans and mass spectrometry analysis

Upon thawing, sperm cells were collected by centrifugation at 400 ×g for 5 min, washed twice with phosphate buffered saline, and digested with 20 µl Proteinase K (14–22 mg/ml, Roche) at 45°C for 20 hours. After removing insoluble materials by centrifugation, supernatants were treated with 0.5M NaOH containing 1M NaBH4 at 37°C for 20 hours. Samples were passed through Sephadex G-25 equilibrated with water, and materials eluting in the void volume were pooled and applied to a Sephadex G-50 super fine column equilibrated with 0.2 M NaCl. Neutral sugars were monitored by the anthrone color reaction [28], and glycopeptides carrying large glycans or polyLacs were collected for mass spectrometry analysis. The sample was permethylated for MALDI-MS and MS/MS analyses using conditions as described for recovering both non-sulfated and sulfated glycans [29].

2.6. Preparation of seminal fluid polyLacs

Human seminal fluid was prepared from a pool of samples. Semen was mixed with 3 volumes of chloroform:methanol (2:1, v/v) to extract lipids. After centrifugation, the pellet was suspended with 0.1 M Tris-HCl buffer, pH 8.0, containing 1 mM EDTA, and digested by protease K (20 µg/ml) at 45°C for 20 hours. After centrifugation at 12,000 ×g for 30 min, water soluble materials were passed through Sephadex G-25 equilibrated with water, and materials eluting in the void volume were applied to a Sephadex G-50 super fine column as described above. PolyLacs were collected and desalted using a Sephadex G-25 column and lyophilized.

2.7. Immunohistochemistry

Paraffin-embedded sections of human testis, epididymis, and ductus deferens tissues were obtained from Folio Biosciences (Columbus, OH). After deparaffinization, hydration and peroxide-treatment, one of each paired slides was subjected to EBG treatment at 37°C for 30 min. Tissue specimens were stained by anti-Lewis Y (clone AH6) antibody [26], followed by biotinylated goat anti-mouse IgM antibody (Vector) and peroxidase-conjugated streptavidin. The peroxidase color reaction was performed using DAB substrate on paraffin-embedded tissue sections or AEC single solution (Invitrogen) on sperm smears, and all tissues were counterstained using hematoxylin. Unwashed and PBS-washed human sperm cells were smeared on glass slides, air-dried and fixed with 4% paraformaldehyde in PBS. Tissues were then treated with or without EBG and immunostained as described above for tissue sections.

2.8. FGF plate binding assay

Human recombinant FGF1 or FGF2 (0.5 µg) was diluted in 100 µl water and added to wells of 96-well polyvinylchloride flat bottom plates (Coster), which were then incubated 20 hours at 4°C. After washing wells with PBST (0.2 M Na-phosphate buffer, pH 7.4, containing 0.2% Tween 20), wells were blocked with Superblock 20 (Pierce). PBST (50 µl) with or without heparin (200 µg/ml) was added to each well and incubated for 15 min at room temperature. Seminal fluid polyLacs (200 µg/ml in PBST, 50 µl) was then added to each well and incubated for 15 min. After washing with PBST, diluted (1:3000) anti-LeY antibody (AH6) [26] was added to wells and reacted at room temperature for 60 min. After washing with PBST, diluted (1:2000) peroxidase-conjugated anti-mouse IgM antibody was added and reacted at room temperature for 30 min. After washing with PBST, wells were reacted with TBM substrate solution (eBioscience) at room temperature for 30 min for peroxidase-based color reaction. The color reaction was stopped by addition of 2N-sulfuric acid, and absorbance at 450 nm was measured in a plate reader.

2.9. Glycan arrays

Glycan microarrays were printed as described [30]. For the analysis, v5.1 ( was used. Recombinant FGF2 was diluted to 200 µg/ml in TBSCM (20 mM Tris, 150 mM NaCl, 2 mM CaCl2, 2 mM MgCl2, pH 7.4) containing 1% bovine serum albumin and 0.05 % Tween-20, with or without 100 µg/ml heparin. A 70 µl aliquot was applied to a microarray slide and incubated for 60 min under a coverslip in a humidified chamber at room temperature. Coverslips were then gently removed in a solution of TBSCM/0.05% Tween-20 and subjected to the TBS standard wash procedure. To detect protein binding, the slide was similarly incubated with mouse monoclonal anti-FGF2 antibody (clone bFM2, Millipore) and washed as described. The slide was then incubated in the dark with anti-mouse IgG antibody labeled with Alexa 488 (Qiagen) at 5 µg/ml, washed as described above, and then washed with deionized water to remove salts. The slide was then spun in a slide centrifuge for approximately 15 sec to dry and immediately scanned in a PerkinElmer ProScanArray Scanner using an excitation wavelength of 488 nm and ImaGene software (BioDiscovery, Inc.) to quantify fluorescence. Data are reported as the average RFU of 4 of 6 replicates (after removal of highest and lowest values) for each glycan represented on the array.

2.10. FGF binding to HEK293T cells

HEK293T cells were cultured to ~75% confluency. To assay FGF binding to its receptor, medium was completely replaced with fresh medium containing 10% fetal calf serum and 1 mM Na3VO4 for 30 min. PolyLacs purified as described above were added to the monolayer at 1 mg/ml and incubated for 10 min. Recombinant b-FGF (Sigma) was then added to a final concentration of 25 ng/ml and incubated for 5 min. Cells were then washed three times with TBS. Cell lysates were prepared with lysis buffer provided in the b-FGF ELISA kit (Ray Biotech), followed by centrifugation. Each lysate containing 100 mg protein was subjected to an ELISA inhibition assay to determine the amount of FGF bound to cells in the presence or absence of polyLacs.

2.11. Immunoprecipitation and immunoblotting

HEK293T cells were cultured in medium supplemented with 10% fetal calf serum. Na3VO4 was added to a final concentration of 1 mM and incubated for 30 min. FGF was added to a final concentration of 25 ng/ml in the presence or absence of polyLacs (1 mg/ml) and incubated for 5 min. Cell were collected using a rubber policeman, washed with cold TBS containing 1 mM Na3VO4, and lysed with 1% NP-40 in TBS. Each lysate was pre-cleared with 20 ul protein A/G agarose beads at 4°C for 20 hours. Protein A/G beads (20 µl) were then coated with anti-FGFR2 antibody (2 µg, rabbit polyclonal, GenTex) in 500 µl TBST at 4C for 20 hours. Pre-cleared lysates were reacted with antibody-coated beads at 4°C for 20 hours. Beads were washed three times with TBST and bead-bound materials were eluted by boiling in SDS buffer for 3 min. Proteins were resolved on 4–12% gradient SDS-polyacrylamide gels and transferred to an immobilon-P filter (Millipore). After blocking with Odyssey blocking buffer (Li-Cor Biosciences), the filter was reacted with diluted (1:500) anti-tyrosine phosphate antibody (4G10, Upstate Biologicals) in blocking buffer containing 0.1% Tween 20 for 60 min, followed by incubation of diluted (1: 5,000) IRDye-conjugated anti-mouse IgG antibody (Li-Cor Biosciences) for 45 min. After washing with TBST, the filter was scanned by the Odyssey imaging system to detect bands.

2.12. Immunofluorescence microscopy

Semen was smeared on glass slide glasses, air dried and fixed with 4% paraformaldehyde in PBS at room temperature for 15 min. Sperm cells and seminal fluid on the slide glass were reacted with diluted (1:100) anti-FGF2 antibody (rabbit polyclonal, rabbit IgG) and mouse monoclonal anti-LeY (clone AH6, mouse IgM) for 1 hour. Control slide received no primary antibody. After washing with PBS, sample was reacted with A568-labeled anti-rabbit IgG antibody and A488-labeled anti-mouse IgM antibody. After washing with PBS, slides were mounted with Vectashield (Vector) with DAPI.

3. Results

3.1. Effect of EBG on human sperm motility

We analyzed human sperm motility using computer-assisted sperm motility analyzer. This analysis showed that EBG enhanced sperm motility, whereas sperm treated with sialidase and with β-galactosidase showed motility comparable to untreated sperm (Fig. 1AB). Treatment with trypsin did not enhance sperm motility, excluding the possibility that the observed EBG effect is nonspecific.

Fig. 1
Effect of EBG treatment on human sperm

Sperm tail motility reportedly requires ATPase and ion channel activities [3133]. To begin to analyze these parameters, we measured calcium levels in sperm and observed that they were significantly increased in EBG-treated sperm cells (Fig. 1C). Since calcium flux into sperm is mediated by cyclic nucleotide-dependent gated channels [31], we examined cAMP levels and found that they were indeed enhanced in EBG-treated sperm cells (Fig. 1D, Fig. S1). These results suggested that polyLacs attached to the sperm tail suppressed sperm motility through a cAMP- and calcium channel-dependent mechanism.

3.2. Isolation and characterization of sperm-associated polyLacs

As a previous study of human sperm glycans did not detect polyLacs [34], we hypothesized that polyLacs are not an intrinsic component of human sperm but are derived from seminal fluid and associated with the tail. To characterize sperm-associated polyLacs, we isolated sperm cells from semen washed twice with PBS. Sperm cells were then digested with protease K, and water-soluble materials were fractionated by gel filtration. This analysis revealed the existence of large carbohydrates, presumably polyLacs (Fig. 2A-a). Following EBG treatment, a substantial portion of large carbohydrates was converted to smaller fragments, demonstrating that they are indeed polyLacs (Fig. 2A-b).

Fig. 2
Structure and localization of sperm-associated large glycans

MALDI-MS analysis of sperm-associated polyLacs revealed the presence of sulfated, sialylated, fucosylated Hex-HexNAc units (Fig. 2B). Notably, the presence of blood group H antigen, LeX antigen and LeY antigen was evident based on both composition and additional MS/MS analysis (Table S1). In particular, in-source prompt fragmentation yielded oxonium ions at m/z 638 and 812, corresponding to LacNAc with 1 and 2 Fuc, respectively. Furthermore, glycan fragments with compositions such as 3 LacNAc and 4 Fuc with and without additional sulfate were detected. Thus the internal portion of polyLacs was highly substituted with fucose, in addition to sialylation and sulfation seen at the termini.

To determine the origin of sperm-associated polyLacs, we performed immunohistochemistry of human tissue from organs functioning in spermatogenesis using anti-Lewis Y antibody in tissues treated with or without EBG. While testis was negative for LeY antigen (Fig. 3-a), LeY antigen was seen in epithelial cells of tissue from epididymis, which contains spermatozoa newly released from testis (Fig. 3-b) and from ductus deferens, which contains fully matured spermatozoa (Fig. 3-c). A semen smear, which contains a mixture of sperm cells and seminal fluid, was positive for LeY antigen (Fig. 3-d), but LeY antigen was lost from these tissue sections after EBG treatment (Fig. 3-cd, right panels). A twice-washed spermatozoa smear treated with EBG showed loss of LeY positivity (Fig. 3-e). These results strongly suggest that LeY antigenic polyLacs attached to mature sperm cells were secreted from epithelial cells of the epididymis and/or ductus deferens into seminal fluid.

Fig. 3
Immunohistochemistry of tissue sections and sperm smears using anti-Lewis Y antibody

3.3. Binding of polyLacs to FGF

Increased cAMP levels seen in EBG-treated sperm (Fig. 1D) suggested a role for FGF signaling in the process, since FGF activated the FGFT to increase cAMP to increase cAMP levels through the PLCµ/Ca2+/PKC pathway [35]. We tested polyLac binding to FGFs by a plate assay, using plates coated either by recombinant FGF1 or FGF2. Seminal fluid polyLac bound to both FGF1 and FGF2 (Fig. 4AB), whereas the same polyLacs did not bind to epidermal growth factor (Fig. 4B). Glycan array analysis confirmed FGF2 binding to sulfated glycans and fucosylated and nonfucosylated polyLac structures (Fig. 4C). Immunofluorescence microscopy of human semen showed co-localization of FGF2 and LeY (Fig. S2).

Fig. 4
Binding of seminal fluid polyLacs to FGF

It is known that FGFs interact with heparin and/or heparan sulfate, which is essential for FGFR binding and subsequent signaling [36,37]. We asked if polyLacs bind to FGF at the heparin-binding site, by testing the effect of heparin on polyLac binding to FGF by plate assay (Fig. 4D). Results clearly showed that heparin has no inhibitory effect of polyLac binding to FGF1 and FGF2.

3.4. Effect of polyLacs on FGF signaling

The results described above suggest that FGF binds to polyLacs, potentially hindering FGF binding to cell surface receptors and attenuating FGF signaling. Since polyLacs and FGF are expressed in many cell types, we asked whether this effect occurs in other cell types. To do so, we employed HEK293T cells, since a publicly available gene expression database indicates that this line expresses high levels of FGFR2 mRNA. Binding of FGF to HEK293T cells was significantly higher in the absence of seminal fluid polyLacs compared to binding in the presence of polyLacs (Fig. 5A), suggesting that these glycans block FGF binding to the receptor. Moreover, following addition of FGF to HEK293T cells, FGFR2 became tyrosine-phosphorylated, with activity peaking in 5 minutes (Fig. 5B), whereas FGFR2 tyrosine phosphorylation at that time point was inhibited by seminal fluid polyLacs (Fig. 5C).

Fig. 5
Effect of polyLacs on FGF signaling in HEK293T cells

Above described results suggest a possibility that removal of polyLacs and supplementing FGF increases FGF signaling. We tested this hypothesis by comparing human sperm motility following treatment with EBG, FGF or both. EBG or FGF treatment increased motility relative to untreated control sperm, but the highest motility was observed in sperm treated with both (Fig. 5D).

4. Discussion

Here, we show that human sperm tail is heavily covered by fucosylated, sialylated and sulfated polyLacs. EBG treatment removed these glycans from the sperm tail, leading to increased motility, calcium influx and increased cAMP levels (Fig. 1). Therefore we propose that mechanisms underlying sperm motility require cAMP signaling, which potentially targets sperm-specific calcium transporters, such as CatSpers [38,39] (Fig. 5E).

Several studies have reported structures of glycans isolated from seminal fluid glycoproteins, including a1-acid glycoprotein [40], clusterin, galectin-3-binding glycoprotein, prostatic acid phosphatase, protein C inhibitor [41], and glycodelin [42,43]. However, polyLacs were not found in these glycoproteins. It is likely that the polyLacs characterized here are carried by a specific carrier protein, which have yet to identify. Identification of a seminal fluid glycoprotein carrying polyLacs may provide important insight into regulation of sperm motility.

We showed in this study that FGFs bind to complex glycans of which structures are shared with seminal fluid polyLacs (Fig. 4C). It is known that heparin and heparan sulfate bind to both FGF and FGFR, which promotes the ligand-receptor binding and tyrosine phosphorylation of FGFR [35,37]. However, our binding assays, including the glycan array, did not demonstrate polyLac binding to FGFR (data not shown). By contrast, polyLacs bound to FGFs (Fig. 4). Interestingly, heparin did not inhibit polyLac binding to FGFs (Fig. 4D), suggesting that polyLacs binds to FGF at the site distinct from heparin binding site. Furthermore, it appears that binding of polyLacs to FGFs was enhanced in the presence of heparin. This effect was clearly demonstrated by binding of sulfated polyLac, keratin sulfate, to FGF2: binding of keratin sulfate was elevated in the presence of heparin (Fig. S3). These observations not only exclude a possibility that polyLacs attenuate FGF signaling by inhibiting heparin binding to FGF, but also suggest a possibility that heparin-bound FGF change its conformation to be favorable for polyLac binding.

We show here that tyrosine phosphorylation of FGFR2 in HEK293T cells grown under normal tissue culture conditions is down-regulated by seminal fluid polyLacs (Fig. 5ABC). This finding suggests that polyLac-mediated regulation of FGF occurs in a variety of tissue types. Thus, we conclude that sperm cells employ a conserved mechanism requiring highly concentrated polyLacs to regulate motility.


  • We found that human sperm treated with endo-β-galactosidase enhanced motility.
  • Sperm-associated poly-N-acetyllactosamine type glycans are heavily fucosylated, consistent with Lewis Y antigen.
  • Immunohistochemistry of tissues involved in spermatogenesis suggested that endo-β-galactosidase susceptible Lewis Y antigen is synthesized by epithelia in epididymis.
  • Endo-β-galactosidase-treated sperm elevated cAMP and calcium influx, suggesting an activation of fibroblast growth factor signling pathway.
  • Seminal fluid polylactosamines bound to fibroblast growth factors and impaired their receptor-mediated signaling.


This study was supported by National Institutes of Health Grants CA33859 and EY014620, Sanford-Burnham Medical Research Institute, La Jolla, California, USA, a Grant-in-Aid for Scientific Research B-23390388 and Challenging Exploratory Research 24659726 from the Japan Society for the Promotion of Science, Hamamatsu University School of Medicine, Shizuoka, Japan, and the Taiwan National Core Facility Program for Biotechnology, NSC grant 100-2325-B-001-029, Academia Sinica, Taipei, Taiwan. The authors thank Dr. Elise Lamar for editing the manuscript, and Xiayu Stacy Huang for assistance with statistical analysis. We thank Drs. David F. Smith and Jamie Heimburg-Molinaro for glycan array provided as core H by the Consortium for Functional Glycomics supported by NIH grants GM62116 and GM098791.


1. Jarnefelt J, Rush J, Li YT, Laine RA. Erythroglycan, a high molecular weight glycopeptide with the repeating structure [galactosyl-(1 leads to 4)-2-deoxy-2-acetamido-glucosyl(1 leads to 3)] comprising more than one-third of the protein-bound carbohydrate of human erythrocyte stroma. J Biol Chem. 1978;253:8006–8009. [PubMed]
2. Muramatsu T, Gachelin G, Damonneville M, Delarbre C, Jacob F. Cell surface carbohydrates of embryonal carcinoma cells: polysaccharidic side chains of F9 antigens and of receptors to two lectins, FBP and PNA. Cell. 1979;18:183–191. [PubMed]
3. Fukuda M, Fukuda MN, Hakomori S. Developmental change of genetic deficiency inthe carbohydrate structure of band 3 of human erythrocyte membrane. J.Biol.Chem. 1979;254:3700–3703. [PubMed]
4. Fukuda M, Dell A, Oates JE, Fukuda MN. Structure of branched lactosaminoglycan, the carbohydrate moiety of band 3 isolated from adult human erythrocytes. J Biol Chem. 1984;259:8260–8273. [PubMed]
5. Spooncer E, Fukuda M, Klock JC, Oates JE, Dell A. Isolation and characterization of polylfucosylated lactosaminoglycan from human granulocytes. J.Biol.Chem. 1984;259:4792–4801. [PubMed]
6. Fenderson BA, O'Brien DA, Millette CF, Eddy EM. Stage-specific expression of three cell surface carbohydrate antigens during murine spermatogenesis detected with monoclonal antibodies. Dev Biol. 1984;103:117–128. [PubMed]
7. Fukuda MN, Fukuda M, Hakomori S. Cell surface modification by endo-beta-galactosidase. Change of blood group activities and release of oligosaccharides from glycoproteins and glycosphingolipids of human erythrocytes. J Biol Chem. 1979;254:5458–5465. [PubMed]
8. Hakomori S. Blood group ABH and Ii antigens of human erythrocytes : chemistry, polymorphism and their developmental change. Seminars in Hematology. 1981;18:39–62. [PubMed]
9. Feizi T. Demonstration by monoclonal antibodies that carbohydrate structures of glycoproteins and glycolipids are onco-developmental antigens. Nature. 1985;314:53–57. [PubMed]
10. Fenderson BA, Holmes EH, Fukushi Y, Hakomori S. Coordinate expression of X and Y haptenes during murine embryogenesis. Developmental Biology. 1986;114:12–21. [PubMed]
11. Liu J, et al. Lewis y antigen promotes the proliferation of ovarian carcinoma-derived RMG-I cells through the PI3K/Akt signaling pathway. J Exp Clin Cancer Res. 2009;28:154. [PMC free article] [PubMed]
12. Kannagi R, Izawa M, Koike T, Miyazaki K, Kimura N. Carbohydrate-mediated cell adhesion in cancer metastasis and angiogenesis. Cancer Sci. 2004;95:377–384. [PubMed]
13. Zhu BC, Fisher SF, Pande H, Calaycay J, Shively JE, Laine RA. Human placental (fetal) fibronectin: increased glycosylation and higher protease resistance than plasma fibronectin. Presence of polylactosamine glycopeptides and properties of a 44-kilodalton chymotryptic collagen-binding domain: difference from human plasma fibronectin. J Biol Chem. 1984;259:3962–3970. [PubMed]
14. Carlsson SR, Roth J, Piller F, Fukuda M. Isolation and characterization of human lysosomal membrane glycoproteins, h-lamp-1 and h-lamp-2, major sialoglycoproteins carrying polylactosaminoglycan. J.Biol.Chem. 1988;263:18911–18919. [PubMed]
15. Tanaka Y, et al. Accumulation of autophagic vacuoles and cardiomyopathy in LAMP-2-deficient mice. Nature. 2000;406:902–906. [PubMed]
16. Togayachi A, Kozono Y, Kuno A, Ohkura T, Sato T, Hirabayashi J, Ikehara Y, Narimatsu H. Beta3GnT2 (B3GNT2), a major polylactosamine synthase: analysis of B3GNT2-deficient mice. Methods Enzymol. 2010;479:185–204. [PubMed]
17. Zhou D, Dinter A, Gutierrez Gallego R, Kamerling JP, Vliegenthart JF, Berger EG, Hennet T. A beta-1,3-N-acetylglucosaminyltransferase with poly-N-acetyllactosamine synthase activity is structurally related to beta-1,3-galactosyltransferases. Proc Natl Acad Sci U S A. 1999;96:406–411. [PubMed]
18. Shiraishi N, et al. Identification and characterization of three novel beta 1,3-Nacetylglucosaminyltransferases structurally related to the beta 1,3-galactosyltransferase family. J Biol Chem. 2001;276:3498–3507. [PubMed]
19. Seko A, Yamashita K. Activation of beta1,3-N-acetylglucosaminyltransferase-2 (beta3Gn-T2) by beta3Gn-T8. Possible involvement of beta3Gn-T8 in increasing poly-N-acetyllactosamine chains in differentiated HL-60 cells. J Biol Chem. 2008;283:33094–33100. [PubMed]
20. Seko A, Yamashita K. beta1,3-N-Acetylglucosaminyltransferase-7 (beta3Gn-T7) acts efficiently on keratan sulfate-related glycans. FEBS Lett. 2004;556:216–220. [PubMed]
21. Kitayama K, Hayashida Y, Nishida K, Akama TO. Enzymes responsible for synthesis of corneal keratan sulfate glycosaminoglycans. J Biol Chem. 2007;282:30085–30096. [PubMed]
22. Tollner TL, et al. A common mutation in the defensin DEFB126 causes impaired sperm function and subfertility. Sci Transl Med. 2011;3 92ra65. [PMC free article] [PubMed]
23. Hatakeyama S, Sugihara K, Lee SH, Nadano D, Nakayama J, Ohyama C, Fukuda MN. Enhancement of human sperm motility by trophinin binding peptide. J Urol. 2008;180:767–771. [PubMed]
24. Fukuda MN. Purification and characterization of endo-beta-galactosidase from Escherichia freundii induced by hog gastric mucin. J.Biol.Chem. 1981;256:3900–3905. [PubMed]
25. Fukuda MN, Matsumura G. Endo-beta-galactosidase of Escherichia freundii. Purification and endoglycosidic action on keratansulfates, oligosaccharides, and blood group active glycoproteinJBiol. Chem. 1976;251:6218–6225. [PubMed]
26. Abe K, McKibbin JM, Hakomori S. The monoclonal antibody directed to difucosylated type 2 chain (Fuc alpha 1 leads to 2Gal beta 1 leads to 4[Fuc alpha 1 leads to 3]GlcNAc; Y Determinant) J Biol Chem. 1983;258:11793–11797. [PubMed]
27. Hoogewijs M, De Vliegher S, De Schauwer C, Govaere J, Smits K, Hoflack G, de Kruif A, Van Soom A. Validation and usefulness of the Sperm Quality Analyzer V equine for equine semen analysis. Theriogenology. 2011;75:189–194. [PubMed]
28. Trevelyan WE, Harrison JS. Studies on Yeast Metabolism 1. Fractionation and microdetermination of cell carbohydrates Biochem J. 1952;50:298–303. [PubMed]
29. Khoo KH, Yu SY. Mass spectrometric analysis of sulfated N- and O-glycans. Methods Enzymol. 2010;478:3–26. [PubMed]
30. Blixt O, et al. Printed covalent glycan array for ligand profiling of diverse glycan binding proteins. Proc Natl Acad Sci U S A. 2004;101:17033–17038. [PubMed]
31. Ren D, Navarro B, Perez G, Jackson AC, Hsu S, Shi Q, Tilly JL, Clapham DE. A sperm ion channel required for sperm motility and male fertility. Nature. 2001;413:603–609. [PubMed]
32. Turner RM. Moving to the beat: a review of mammalian sperm motility regulation. Reprod Fertil Dev. 2006;18:25–38. [PubMed]
33. Wald M. Enhancement of human sperm motility. J Urol. 2008;180:442–443. [PubMed]
34. Pang PC, Tissot B, Drobnis EZ, Sutovsky P, Morris HR, Clark GF, Dell A. Expression of bisecting type and Lewisx/Lewisy terminated N-glycans on human sperm. J Biol Chem. 2007;282:36593–36602. [PubMed]
35. Mohammadi M, et al. A tyrosine-phosphorylated carboxy-terminal peptide of the fibroblast growth factor receptor (Flg) is a binding site for the SH2 domain of phospholipase C-gamma 1. Mol Cell Biol. 1991;11:5068–5078. [PMC free article] [PubMed]
36. Klagsbrun M. Mediators of angiogenesis: the biological significance of basic fibroblast growth factor (bFGF)-heparin and heparan sulfate interactions. Semin Cancer Biol. 1992;3:81–87. [PubMed]
37. Yayon A, Klagsbrun M, Esko JD, Leder P, Ornitz DM. Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell. 1991;64:841–848. [PubMed]
38. Carlson AE, Westenbroek RE, Quill T, Ren D, Clapham DE, Hille B, Garbers DL, Babcock DF. CatSper1 required for evoked Ca2+ entry and control of flagellar function in sperm. Proc Natl Acad Sci U S A. 2003;100:14864–14868. [PubMed]
39. Cotton LM, O'Bryan MK, Hinton BT. Cellular signaling by fibroblast growth factors (FGFs) and their receptors (FGFRs) in male reproduction. Endocr Rev. 2008;29:193–216. [PubMed]
40. Poland DC, Kratz E, Vermeiden JP, De Groot SM, Bruyneel B, De Vries T, Van Dijk W. High level of alpha1-acid glycoprotein in human seminal plasma is associated with high branching and expression of Lewis(a) groups on its glycans: supporting evidence for a prostatic origin. Prostate. 2002;52:34–42. [PubMed]
41. Clark GF, et al. Tumor biomarker glycoproteins in the seminal plasma of healthy human males are endogenous ligands for DC-SIGN. Mol Cell Proteomics. 2011;11 M111 008730. [PubMed]
42. Koistinen H, et al. Glycodelin from seminal plasma is a differentially glycosylated form of contraceptive glycodelin-A. Mol Hum Reprod. 1996;2:759–765. [PubMed]
43. Morris HR, et al. Gender-specific glycosylation of human glycodelin affects its contraceptive activity. J Biol Chem. 1996;271:32159–32167. [PubMed]